Full Text of PDF (973k)
Article in Japanese
Abstract
Topics Series Advances in lung cancer therapy
Novel development for immunotherapy in patients with lung cancer
Ryo Ko Takehito Shukuya Kazuhisa Takahashi
Department of Respiratory Medicine, Juntendo University School of Medicine
ABSTRACT
The treatment of cancer by harnessing immune responses has long been pursued; however, the effect has met with limited success. But recently, increasing knowledge about how the immune system is activated has brought on new strategies of immunotherapy. The latest trials of therapeutic vaccines and immune checkpoint inhibitors have yielded promising results. In particular, the immune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed death 1 (PD-1) pathway have shown meaningful clinical responses with manageable toxicities. In the near future, immunotherapies will be able to provide great benefits to many patients.
KEYWORDS
Lung cancer Immunotherapy CTLA-4 PD-1 Antitumor vaccine
AJRS, 3(1): 43-49, 2014
Copyright © The Japanese Respiratory Society All Rights Reserved.